clinical trial · NCT07026916
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Metastatic Pancreatic CancerGFH375
brief summary
This is a multicenter, open-label, phase II study to explore the efficacy, safety/tolerability and pharmacokinetics (PK) of GFH375 in in Patients with Previously Treated KRAS G12D Mutant Metastatic Pancreatic Cancer.
started
Aug 1, 2025
primary completion
Aug 1, 2027
completion
Aug 1, 2028
last updated
Nov 17, 2025
official title
A Single-Arm, Multicenter, Open-Label, Phase II Clinical Study to Evaluate the Efficacy, Safety/Tolerability, and Pharmacokinetic Characteristics of GFH375 Monotherapy in Patients With Previously Treated KRAS G12D Mutant Metastatic Pancreatic Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol